Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses
A. D. Zelenetz
Advertisement
Articles by A. D. Zelenetz
Iodine-131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of patients with low-grade or transformed low-grade non-Hodgkin’s lymphoma. The data from five phase I-III studies, which enrolled patients with low-
Advertisement
Latest Updated Articles
- Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data
Published: March 1st 2001 | Updated:
- Iodine I 131 Tositumomab for Patients With Follicular Non-Hodgkin’s Lymphoma (NHL): Overall Clinical Trial Experience by Histology
Published: March 1st 2000 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
3
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
